Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cardiol to Advance CardiolRx into a Late-stage Trial in Recurrent Pericarditis
Details : CardiolRx (cannabidiol) is an oral solution that works by inhibiting activation of the NLRP3 inflammasome. It is being evaluated for recurrent pericarditis.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 22, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Details : CardiolRx (pure cannabidiol solution) which is a NLRP3 inflammasome inhibitor. It is being evaluated for the treatment of recurrent pericarditis.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx™ (cannabidiol), is a oral solution formulation being developed for use in heart diseases. Cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis a...
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 07, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ (Cannabidiol) inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Recurrent Pericarditis and inhibits activation of the inflammasome pathway.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Acute Myocarditis and inhibits activation of the inflammasome pathway.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19.
Brand Name : CardiolRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 18, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?